1. Basic Information
Disease Protected Against
Coronavirus Disease 2019 (COVID-19), caused by SARS-CoV-2, ranges from asymptomatic infection to severe respiratory failure, multiorgan dysfunction, and death. Children generally experience milder acute disease than adults, but severe outcomes — including MIS-C (Multisystem Inflammatory Syndrome in Children), hospitalization, and death — occur. As of 2024, COVID-19 remains a leading cause of pediatric respiratory hospitalization during seasonal waves. Post-acute sequelae ("Long COVID") are reported in children at lower rates than adults but are not negligible (~1–5% prevalence estimates vary by case definition and study design).
CDC Schedule (U.S., 2025)
| Population | Recommendation |
|---|---|
| All persons ≥6 months | Universal recommendation for COVID-19 vaccination; updated formulations matched to circulating variants |
| Children 6 months–4 years (unvaccinated) | 2–3 dose primary series (depending on product and age) |
| Children 6 months–4 years (previously vaccinated) | 1 dose of updated vaccine |
| Children ≥5 years (unvaccinated) | 1 dose of updated mRNA vaccine, or 2-dose Novavax primary series |
| Children ≥5 years (previously vaccinated) | 1 dose of updated vaccine |
| Immunocompromised | Additional doses per ACIP guidance |
Source: CDC ACIP, 2025 schedule. As of the 2024–25 season, updated vaccine formulations target circulating variants (transitioning from the bivalent BA.4/5 formulation to monovalent formulations matched to Omicron sublineages such as JN.1, KP.2, etc.).
Licensed/Authorized Products (U.S., Pediatric)
- Comirnaty® (Pfizer-BioNTech, BNT162b2) — mRNA vaccine. Licensed for ages ≥12 (August 2021); EUA for ages 6 months–11 years. Encodes the SARS-CoV-2 spike protein. Lipid nanoparticle (LNP) formulation.
- Spikevax® (Moderna, mRNA-1273) — mRNA vaccine. Licensed for ages ≥18; EUA for ages 6 months–17 years. Also spike-protein-encoding mRNA in LNP.
- Novavax COVID-19 Vaccine (NVX-CoV2373) — Recombinant spike protein subunit vaccine with Matrix-M adjuvant. Authorized for ages ≥12. Represents a non-mRNA option using more traditional protein-based technology.
- Janssen COVID-19 Vaccine (Johnson & Johnson, Ad26.COV2.S) — Adenoviral vector vaccine. No longer available in the U.S. (EUA revoked June 2023). Noted here for completeness because safety signals identified with this product (TTS/VITT — thrombosis with thrombocytopenia syndrome) are important to the overall COVID-19 vaccine safety narrative.
2. Pre-Licensure Clinical Trial Data
COVID-19 vaccines underwent the largest and most rapidly conducted pre-licensure clinical trial programs in history, under Emergency Use Authorization (EUA) frameworks that required demonstration of safety and efficacy but allowed for accelerated review timelines.
Pivotal Trial Data — Pediatric Populations
| Product | Pediatric Pivotal Trial Size | Efficacy/Immunobridging |
|---|---|---|
| Pfizer (ages 12–15) | ~2,260 (1,131 vaccine, 1,129 placebo); C4591001 trial | 100% efficacy (95% CI 75–100) against symptomatic COVID-19; short follow-up period |
| Pfizer (ages 5–11) | ~3,100 (2:1 randomization); immunobridging design | 90.7% efficacy (95% CI 67.7–98.3) |
| Pfizer (ages 6 months–4 years) | ~4,500 (3-dose series); immunobridging | Immunobridging to young adults met; limited clinical efficacy data due to low case counts |
| Moderna (ages 12–17) | ~3,700 | ~93% efficacy (against original strains); immunobridging met |
| Moderna (ages 6–11) | ~4,000; immunobridging | Immunobridging met |
| Moderna (ages 6 months–5 years) | ~6,400 (2-dose series); immunobridging | Immunobridging met; efficacy against symptomatic infection ~37–51% during Omicron |
Note: Efficacy estimates were generated during periods of specific variant predominance (e.g., original strain, Alpha, Delta). Effectiveness against Omicron sublineages and more recent variants is lower, particularly against infection, though protection against severe disease is better preserved.
Most Common Adverse Reactions (mRNA Vaccines, Children)
| Reaction | Adolescents (12–17) | Children (5–11) | Young Children (6m–4y) |
|---|---|---|---|
| Injection site pain | ~80–90% | ~70–80% | ~30–50% |
| Fatigue | ~50–65% | ~35–45% | ~25–35% |
| Headache | ~45–60% | ~25–35% | ~10–15% |
| Myalgia | ~35–50% | ~15–25% | ~8–12% |
| Fever | ~10–20% | ~8–15% | ~8–15% |
| Chills | ~25–35% | ~8–12% | ~3–5% |
Sources: Pfizer and Moderna pivotal trial data; FDA VRBPAC briefing documents. Reactogenicity is generally dose-dependent (higher with the second dose of a primary series; data on updated formulations are more limited). Adverse reactions in children are less frequent and less severe than in adults.
Key Limitations of Pre-Licensure Trial Data
- Short follow-up duration: The median safety follow-up in the pediatric EUA submissions was ~2–3 months post-dose 2. This was adequate to detect common acute adverse events but inherently limited for evaluating long-term outcomes or rare events with longer latency.
- Small sample sizes relative to adult trials: Pediatric trials were substantially smaller than the adult pivotal trials (Pfizer adult: ~44,000; Pfizer 12–15: ~2,260). Rare adverse events — especially myocarditis, which occurs at ~1–10 per 100,000 in adolescent males — were not expected to be detected in pre-licensure pediatric trials.
- Evolving variant landscape: Efficacy estimates from the pre-Omicron era are not directly applicable to current circulating variants. Effectiveness is now assessed primarily through post-licensure observational studies.
- Immunobridging endpoints: Pediatric licensure was based primarily on immunobridging (demonstrating non-inferior neutralizing antibody titers compared to young adults in whom clinical efficacy was demonstrated), not direct clinical efficacy, with the exception of the 12–15-year Pfizer trial.
3. Post-Licensure Safety Data
Myocarditis / Pericarditis — Confirmed Safety Signal (mRNA Vaccines)
An elevated risk of myocarditis and pericarditis following mRNA COVID-19 vaccination (particularly the second dose) was identified in post-licensure surveillance beginning in mid-2021. This is the most significant confirmed pediatric safety signal for COVID-19 vaccines.
- Highest-risk group: Adolescent and young adult males aged 12–29. Risk is highest after the second dose of a primary series.
- Rate estimates (VSD and international data): Pfizer: ~2–10 cases per 100,000 doses in males aged 12–17; ~5–15 per 100,000 in males aged 18–29. Moderna: some data suggest a slightly higher rate than Pfizer (possibly ~2–3x higher in young adult males), though data in children are less extensive.
- Risk after booster doses: Lower than after the second primary dose, though data are more limited.
- Clinical course: The majority of cases are mild and self-limited, with symptom resolution within days to weeks and normal cardiac MRI findings at follow-up. However, a small proportion require ICU admission, and long-term cardiac outcomes are still being studied.
- Comparison to COVID-19-associated myocarditis: Myocarditis risk following SARS-CoV-2 infection is substantially higher (~10–40x) than the risk following mRNA vaccination across most age/sex strata. COVID-19 infection itself is a well-established cause of myocarditis.
IOM / NASEM have not yet issued a comprehensive causality assessment for COVID-19 vaccines (as of the 2012 report which predates these products). The CDC and FDA have acknowledged the association and incorporated it into product labeling and clinical guidance.
Other VSD / Active Surveillance Findings (Pediatric)
- Anaphylaxis: Estimated at ~2–5 per million doses for mRNA vaccines. Comparable to or slightly higher than rates for other vaccines.
- Febrile seizures: A VSD study (Goddard et al., 2023) found a small increased risk of febrile seizures in children aged 2–5 following concomitant administration of mRNA COVID-19 vaccine and IIV (influenza). Rate was ~1 excess seizure per 2,500–4,000 concomitant administrations. The signal was not observed with COVID-19 vaccine alone or IIV alone.
- Multisystem Inflammatory Syndrome in Children (MIS-C): No evidence that COVID-19 vaccination causes MIS-C. Multiple studies suggest vaccination reduces MIS-C risk, consistent with MIS-C being a post-infectious complication prevented by vaccination.
- No increased risk for GBS, VTE, stroke, or other thromboembolic events identified with mRNA vaccines in children (unlike the Janssen TTS/VITT signal in adults, which is product-specific).
Janssen (J&J) Specific Safety Signals (Not a Pediatric Product; Noted for Context)
- Thrombosis with Thrombocytopenia Syndrome (TTS/VITT): ~3–4 cases per million doses in adults (highest in females aged 30–49). Causal mechanism involves anti-PF4 antibodies. The J&J EUA was restricted (May 2022) and revoked (June 2023) in the U.S., in part due to this safety signal and the availability of safer alternatives (mRNA vaccines). TTS/VITT is not associated with mRNA vaccines.
- GBS: A small increased risk of GBS (~3–5 per million doses) was observed with Janssen. Not associated with mRNA vaccines after extensive surveillance.
VAERS
| VAERS Metric (COVID-19, cumulative U.S. data) | Approximate Figures |
|---|---|
| Total COVID-19 vaccine doses administered (U.S., through 2024) | >675 million doses |
| Total VAERS reports received for COVID-19 vaccines | >1.5 million (largest VAERS reporting volume for any vaccine in history, reflecting unprecedented scale and stimulated reporting) |
| Reports classified as "serious" | ~6–8% of total reports |
⚠ Critical Caveat
VAERS data represent unverified reports temporally associated with vaccination. A report to VAERS does not mean the vaccine caused the event. The COVID-19 vaccine VAERS database is the largest in history and has been extensively affected by stimulated/heightened reporting due to unprecedented public and media attention. Raw VAERS report counts for COVID-19 vaccines are particularly unsuitable for causal inference, and analyses using VAERS data to claim causality are scientifically invalid.
VAERS Reporting Data — Halma & Varon (2025), DARE-SAFE
The DARE-SAFE paper (Halma & Varon, Pharmacoepidemiology 2025, CC BY 4.0) analyzed VAERS reports for vaccines administered in the United States from 2006–2022. The following data are extracted from Table 1 of that paper for this vaccine (COVID-19 (all mRNA + adenoviral vector products combined). *Dose count from Our World in Data (2021–2022), not the CDC series — different source & time span than other rows (2006–2022 for all other vaccines). See full paper for manufacturer-level breakdowns (Pfizer, Moderna, J&J, Novavax).):
| Metric | Value |
|---|---|
| U.S. doses administered (2006–2022) | 663,000,000* |
| Total VAERS AE reports | 781,075 |
| AE reporting rate (per 100,000 doses) | 117.7 |
| Total death reports | 11,288 |
| Death reporting rate (per 100,000 doses) | 1.70 |
| AE-to-Death ratio | 69:1 |
Source: Halma MT, Varon J. DARE-SAFE. Pharmacoepidemiology. 2025. DOI: 10.3390/pharma4010005. CC BY 4.0. Data from Table 1.
📚 Important Interpretive Caveats (from the paper itself)
- Reporting rate ≠ incidence rate. VAERS is a passive, unverified system. A report means someone submitted a claim of temporal association, not a confirmed causal event. The paper is explicit that causality cannot be inferred from these numbers alone.
- Reporting behavior is not uniform. More serious, unusual, or media-salient events are reported at much higher rates than mild ones. Products receiving more public, media, legal, and clinical attention (particularly COVID-19 vaccines, which also benefited from V-safe active-surveillance prompts and CICP compensation pathways) generate more reports per dose regardless of true risk.
- Age and comorbidity confounding is not adjusted. COVID-19 vaccines were disproportionately administered to elderly and comorbid populations (nursing homes, 65+, high-risk groups in early 2021) with much higher background all-cause mortality than the general child/working-age population. Some fraction of temporally-associated deaths would occur regardless of vaccination, and the paper does not perform a background-rate comparison.
- Stimulated reporting is a known, documented phenomenon. Media coverage, plaintiff attorney solicitation, and advocacy campaigns — all independently inflate VAERS reporting propensity. The paper cites this literature but does not correct for it.
- Small-denominator rows are unreliable. Rates computed from small denominators (e.g., monovalent measles, DT, mumps, rubella) have enormous statistical uncertainty and should not be compared to vaccines with hundreds of millions of administered doses without noting the wide confidence intervals.
Source: Halma MT, Varon J. DARE-SAFE: A data analysis and reporting engine for safety signal detection and pharmacovigilance. Pharmacoepidemiology. 2025;4(1):5. DOI: 10.3390/pharma4010005. CC BY 4.0.
4. Documented Adverse Events — Evidence of Association
▶ Adverse Events with Strong Evidence of Causal Association (mRNA Vaccines)
- Myocarditis / pericarditis: ~2–10 per 100,000 doses in males aged 12–17 after dose 2. Risk is higher with Moderna vs. Pfizer in some datasets. Clinical course is generally mild, but long-term outcomes are still being studied. Risk from SARS-CoV-2 infection is substantially higher. Strong
- Injection site reactions: 80–90% (pain) in adolescents; lower in young children. Strong
- Systemic reactogenicity: Fatigue (50–65%), headache (45–60%), myalgia (35–50%), fever (10–20%) in adolescents after dose 2. Strong
- Anaphylaxis: ~2–5 per million doses. Strong
- Lymphadenopathy (axillary): Tender lymphadenopathy in the ipsilateral axilla, observed in ~5–15% of vaccinees. Self-limited; can cause false-positive findings on mammography and other imaging. Strong
- TTS/VITT (Janssen only — not a pediatric product): ~3–4 per million doses in adults. Causal via anti-PF4 antibodies. Not associated with mRNA vaccines. Strong (Janssen-specific)
▶ Adverse Events with Moderate or Preliminary Evidence
- Febrile seizures (mRNA + concomitant IIV): ~1 per 2,500–4,000 concomitant administrations in children 2–5. Season-specific signal. Moderate
- Long-term cardiac outcomes post-myocarditis: The acute course of mRNA vaccine-associated myocarditis is generally mild, but studies of cardiac function, fibrosis, and exercise tolerance at 1–5 years post-event are ongoing. Limited data preclude firm conclusions about lifelong cardiac risk. Preliminary
- Menstrual irregularities: Multiple observational studies have reported transient changes in menstrual cycle length (~1–2 days) following vaccination. Mechanism uncertain. Changes appear temporary. Moderate
▶ Published Evidence Does Not Support a Causal Association (mRNA Vaccines)
- Infertility (male or female): No evidence of an association. CDC, ACOG, ASRM, and multiple large studies have found no impact on fertility parameters. No Association
- Adverse pregnancy outcomes: Multiple large registry studies (V-safe, VSD, international) have found no increased risk of miscarriage, stillbirth, preterm birth, or congenital anomalies. mRNA vaccination during pregnancy is recommended by ACOG and CDC. No Association
- GBS (mRNA vaccines): After extensive VSD and international surveillance, no increased risk of GBS has been identified with mRNA vaccines (unlike Janssen). No Association
- Death (all-cause mortality): No evidence of increased all-cause mortality associated with mRNA vaccination. Multiple large international studies. No Association
- MIS-C: Vaccination does not cause MIS-C and reduces MIS-C risk by preventing SARS-CoV-2 infection. No Association
5. Disease Prevention Benefits
5a. Pre-Vaccine vs. Post-Vaccine Era (Children & Adolescents, U.S.)
| Metric | Pre-Vaccine Era (2020–2021, Pre-Rollout for Children) | Post-Vaccine Era |
|---|---|---|
| Pediatric COVID-19 hospitalizations (ages 6 months–17) | Peak monthly hospitalization rates of ~1–5 per 100,000 (varies by wave) | Substantially reduced in vaccinated children; VE against pediatric hospitalization ~40–70% during Omicron (protection wanes over time, updated formulations partially restore it) |
| MIS-C incidence | ~300–500 cases/month during Delta/Omicron waves | >80–90% reduction; MIS-C is now rare, predominantly in unvaccinated children |
| Pediatric COVID-19 deaths | ~1,000–1,500 total pediatric deaths (2020–2023 cumulative) | Ongoing but concentrated in unvaccinated children; vaccination reduces death risk |
| SARS-CoV-2 seroprevalence (children) | ~0% (2020) | >95% by 2023 (combined infection- and vaccine-induced) |
Source: CDC COVID Data Tracker; MMWR; Pediatric RSV/COVID-19/Flu hospitalization surveillance. The interpretation of pediatric COVID-19 vaccine effectiveness requires careful attention to variant evolution, waning immunity, and the high background seroprevalence from prior infection — all of which make current VE estimates lower than the >90% efficacy observed in the original trials against ancestral strains.
Current Context
- Protection against severe disease: COVID-19 vaccination continues to provide protection against hospitalization and death in children, though effectiveness wanes over 4–6 months and is partially restored by updated formulations. Pediatric ICU studies consistently show that the majority of critically ill children with COVID-19 are unvaccinated.
- Protection against infection: Effectiveness against symptomatic SARS-CoV-2 infection with Omicron sublineages is modest (~20–40%) and short-lived (2–4 months for infection, somewhat longer for severe disease). This is a marked contrast to the >90% efficacy against original strains.
- Pediatric vaccination coverage: As of 2024, U.S. pediatric COVID-19 vaccination coverage is substantially lower than for other childhood vaccines. Approximately 40–60% of adolescents and 10–20% of children under 5 have completed a primary series. Updated booster coverage is even lower.
6. Evidence Summary — Overall Assessment
Quality and Quantity of Safety Data
The COVID-19 vaccine safety evidence base is the largest in global public health history. More than 675 million doses have been administered in the U.S., and active surveillance through VSD and passive surveillance through VAERS span nearly 5 years. The evidence base includes:
- Large randomized clinical trials (Pfizer adult N=~44,000; Moderna adult N=~30,000; multiple pediatric trials).
- Active surveillance (VSD) covering ~9–10 million persons annually with near-real-time rapid cycle analyses specifically designed for COVID-19 vaccines.
- Passive surveillance (VAERS) with >1.5 million reports — the largest safety database for any medical product in history.
- International surveillance networks (GACVS, EudraVigilance, multiple national registries).
- Targeted epidemiological studies addressing specific safety concerns (myocarditis, TTS/VITT, pregnancy outcomes, menstrual changes).
Areas Where Data Are Robust
- Myocarditis risk (mRNA): The association is well-characterized by age, sex, dose, and product. The clinical course is well-described, though long-term cardiac outcomes are still being studied.
- Acute reactogenicity: Rates of common adverse reactions (injection site pain, fatigue, headache, fever) are precisely characterized across age groups.
- Absence of TTS/VITT with mRNA vaccines: Extensive surveillance has established that TTS/VITT is specific to the adenoviral vector platform and is not associated with mRNA vaccines.
- Absence of GBS with mRNA vaccines: Large VSD and international studies are consistent in finding no association.
- Pregnancy safety: Multiple large, independent datasets are consistent in finding no increased risk of adverse pregnancy outcomes.
- Absence of infertility association: Multiple studies across several countries are concordant.
Areas Where Data Are Limited or Conflicting
- Long-term (>5 years) safety outcomes: COVID-19 vaccines have been in use since December 2020. Follow-up beyond 5 years is not available. This is inherent to the recency of licensure and is not a deficiency specific to these vaccines. Theoretical concerns about long-term effects cannot be definitively addressed until sufficient time has elapsed, though the biological mechanisms of mRNA vaccines (rapid mRNA degradation, transient protein expression) do not suggest plausible long-term adverse effect mechanisms.
- Myocarditis long-term cardiac outcomes: Five-year follow-up data on cardiac function post-vaccine-associated myocarditis in adolescents are not yet available. Preliminary 1–2 year data are generally reassuring, but the evidence is still evolving.
- Effectiveness against current variants: The rapid evolution of SARS-CoV-2 means that efficacy data from the original pivotal trials are not applicable to current variants. All current effectiveness estimates are observational and subject to confounding (prior infection, waning, variant differences).
- Updated vaccine formulations: Each updated formulation (BA.4/5 bivalent, XBB.1.5 monovalent, JN.1/KP.2 monovalent) undergoes more limited pre-licensure testing than the original products, relying on immunobridging and manufacturing process consistency. This is standard for strain-change vaccines (similar to influenza) but limits the pre-licensure safety database for each new formulation.
- Very long-term effects in young children: The youngest vaccinated cohort (6 months–4 years) has the shortest post-licensure follow-up. Data on safety outcomes in this age group are necessarily less extensive than for older children and adults.
Overall Summary Table
| Domain | Evidence Grade | Key Finding |
|---|---|---|
| Prevention of severe COVID-19 (children) | Strong | VE against hospitalization ~40–70% during Omicron; wanes without updated doses |
| Prevention of MIS-C | Strong | >80–90% reduction; MIS-C now rare |
| Prevention of symptomatic infection (Omicron) | Moderate | ~20–40% short-term; limited durability |
| Myocarditis (mRNA) | Strong | ~2–10 per 100,000 in males 12–17; generally mild clinical course |
| Anaphylaxis | Strong | ~2–5 per million doses |
| TTS/VITT (mRNA vaccines) | No Association | Specific to adenoviral vector vaccines (Janssen) |
| GBS (mRNA vaccines) | No Association | Extensive VSD and international data; no signal |
| Infertility | No Association | Multiple large studies; no evidence |
| Adverse pregnancy outcomes | No Association | Multiple large studies; no increased risk |
| Long-term (>5 year) safety | Limited | Insufficient follow-up time; inherent to recency |
7. Key References
- Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–2615. DOI: 10.1056/NEJMoa2034577 (Pfizer adult pivotal trial, N=43,448)
- Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–416. DOI: 10.1056/NEJMoa2035389 (Moderna adult pivotal trial, N=30,420)
- Frenck RW Jr, Klein NP, Kitchin N, et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. N Engl J Med. 2021;385(3):239–250. DOI: 10.1056/NEJMoa2107456 (Pfizer 12–15 trial)
- Walter EB, Talaat KR, Sabharwal C, et al. Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age. N Engl J Med. 2022;386(1):35–46. DOI: 10.1056/NEJMoa2116298
- Oster ME, Shay DK, Su JR, et al. Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from December 2020 to August 2021. JAMA. 2022;327(4):331–340. DOI: 10.1001/jama.2021.24110
- Goddard K, Lewis N, Fireman B, et al. Risk of febrile seizures after co-administration of COVID-19 and influenza vaccines in children. Pediatrics. 2023 (VSD study).
- Shimabukuro TT, Nguyen M, Martin D, DeStefano F. Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS). Vaccine. 2015;33(36):4398–4405. (Describes VAERS methodology)
- See I, Su JR, Lale A, et al. US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination. JAMA. 2021;325(24):2448–2456. (TTS/VITT with Janssen) DOI: 10.1001/jama.2021.7517
- CDC. COVID-19 Vaccine Safety Technical Reports (VaST). cdc.gov/vaccine-safety-systems/covid-19
- CDC. VSD. cdc.gov/vaccine-safety/about/vsd.html
- CDC/FDA. VAERS. vaers.hhs.gov
- CDC. 2025 Child & Adolescent Immunization Schedule. cdc.gov/vaccines/hcp/imz-schedules